Cell Phones Are Now Medical Diagnostic Tools

WASHINGTON, HAARLEM, Netherlands, SHENZHEN, China and HUIZHOU, China /PRNewswire/ -- Gentag Inc. and its partners have just demonstrated a new disposable wireless diagnostic test platform for consumer cell phones. The technology, based on immunoassays, can test for pregnancy, fertility, pathogens, AIDS, drugs, allergens, and even certain types of cancers.

"This technology breakthrough will enable much more rapid diagnoses for diseases and make diagnostics more accessible and affordable for more people worldwide," announced Dr. John Peeters, the founder of Gentag.

Gentag started with well-established immunoassay technology and made it wireless and compatible with Near Field Communication (NFC) technology, which enables consumers to use their cell phones as diagnostic tools to instantly test for pathogens, allergens, or common medical conditions at any time, no matter where they are.

The new technology is expected to broadly impact major women's health markets, including ovulation, fertility, and PROM (labor); men's health market, including a urine-based prostate cancer test (PCADM-1); and tests for common food allergens.

NFC is currently being integrated into all major cell phone brands, and Gentag is working with major OEMs worldwide to promote the uses of its disposable wireless sensor platform for consumer markets.

The new wireless immunoassay technology is expected to rapidly impact the multi-billion dollar markets for OTC diagnostic tests, consumer markets, food safety markets, and homeland security.

For a demonstration of the technology or for information about manufacturing or licensing partnerships, please contact Dr. John Peeters at 240-994-2236 or [email protected].

About Gentag
Gentag Inc. is a technology development company, focusing on the creation of innovative, low-cost, wireless sensor technologies based on cell phones. The company owns a unique intellectual property portfolio, relating to cell-phone sensor combinations and wireless sensor networks and was awarded the 2008 Frost & Sullivan's 2008 North American Award for Technology Innovation.

Suggested Articles

Amphenol Corp. reported today GAAP diluted earnings per share of $1.03 for the fourth quarter of 2019, compared to $1.09 for the 2018 fourth quarter.

Keysight Technologies, Inc. will unveil a design and test workflow solution that reduces product development time for DDRAM systems.

Google CEO Sundar Pichai said EU's GDPR could be starting point for AI regulation, but urged countries to cooperate for a standard approach.